See more : Clio Infotech Limited (CLIOINFO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Zymergen Inc. (ZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zymergen Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Northern Region Cement Company (3004.SR) Income Statement Analysis – Financial Results
- PBF Energy Inc. (PBF) Income Statement Analysis – Financial Results
- Mycotopia Therapies, Inc. (TPIA) Income Statement Analysis – Financial Results
- Limeade, Inc. (LME.AX) Income Statement Analysis – Financial Results
- Kubient, Inc. (KBNTW) Income Statement Analysis – Financial Results
Zymergen Inc. (ZY)
About Zymergen Inc.
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 16.74M | 13.28M | 15.42M |
| Cost of Revenue | 69.72M | 84.82M | 102.64M |
| Gross Profit | -52.98M | -71.53M | -87.22M |
| Gross Profit Ratio | -316.42% | -538.50% | -565.67% |
| Research & Development | 159.12M | 90.85M | 50.72M |
| General & Administrative | 83.01M | 60.08M | 61.25M |
| Selling & Marketing | 23.65M | 18.63M | 24.14M |
| SG&A | 106.66M | 78.70M | 85.39M |
| Other Expenses | 175.51M | 0.00 | 0.00 |
| Operating Expenses | 265.78M | 169.56M | 136.10M |
| Cost & Expenses | 335.50M | 254.37M | 238.74M |
| Interest Income | 64.00K | 492.00K | 4.92M |
| Interest Expense | 14.71M | 10.96M | 2.94M |
| Depreciation & Amortization | 20.70M | 18.71M | 15.20M |
| EBITDA | -326.33M | -232.58M | -218.65M |
| EBITDA Ratio | -1,949.08% | -1,750.80% | -1,418.08% |
| Operating Income | -347.03M | -241.09M | -237.11M |
| Operating Income Ratio | -2,072.68% | -1,814.88% | -1,537.80% |
| Total Other Income/Expenses | -14.71M | -21.15M | 318.00K |
| Income Before Tax | -361.73M | -262.24M | -236.80M |
| Income Before Tax Ratio | -2,160.51% | -1,974.13% | -1,535.74% |
| Income Tax Expense | 51.00K | -49.00K | 8.00K |
| Net Income | -361.79M | -262.19M | -236.80M |
| Net Income Ratio | -2,160.81% | -1,973.76% | -1,535.79% |
| EPS | -4.87 | -2.68 | -2.42 |
| EPS Diluted | -4.87 | -2.68 | -2.42 |
| Weighted Avg Shares Out | 74.31M | 97.94M | 97.94M |
| Weighted Avg Shares Out (Dil) | 74.31M | 97.94M | 97.94M |
Zymergen Advances Molecules for Prominent Malaria and COVID-19 Drug Targets for Further Testing
Zymergen to Present at the 42nd Annual Cowen Healthcare Conference
6 Penny Stocks To Buy For Under $5 With Unusual Options Activity
Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morgan Healthcare Conference
Zymergen Announces Emerging Drug Discovery Business Enabled by One of the World's Largest Metagenomics Databases and Proprietary Synthetic Biology Platform
Zymergen: Total Chaos
ZYMERGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Zymergen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Why Shares of Zymergen Are Skyrocketing Today
The Law Offices of Frank R. Cruz Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Zymergen Inc. (ZY) on Behalf of Investors
Source: https://incomestatements.info
Category: Stock Reports